 | Up a level |
Stathis, Anastasios; Pirosa, Maria Cristina; Orsucci, Lorella; Feugier, Pierre; Tani, Monica; Ghesquières, Hervé; Musuraca, Gerardo; Rossi, Francesca Gaia; Merli, Francesco; Guièze, Romain; Gyan, Emmanuel; Gini, Guido; Marino, Dario; Gressin, Remy; Morschhauser, Franck; Cavallo, Federica; Palombi, Francesca; Conconi, Annarita; Tessoulin, Benoît; Tilly, Hervé; ... (2024). IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. Haematologica - the hematology journal, 109(8), pp. 2564-2573. Ferrata-Storti Foundation 10.3324/haematol.2023.283918
Vannata, Barbara; Pirosa, Maria Cristina; Bertoni, Francesco; Rossi, Davide; Zucca, Emanuele (2022). Bacterial infection-driven lymphomagenesis. Current opinion in oncology, 34(5), pp. 454-463. Lippincott Williams & Wilkins 10.1097/CCO.0000000000000886
Genta, Sofia; Ghilardi, Guido; Cascione, Luciano; Juskevicius, Darius; Tzankov, Alexandar; Schär, Sämi; Milan, Lisa; Pirosa, Maria Cristina; Esposito, Fabiana; Ruberto, Teresa; Giovanella, Luca; Hayoz, Stefanie; Mamot, Christoph; Dirnhofer, Stefan; Zucca, Emanuele; Ceriani, Luca (2022). Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. Cancers, 14(4) MDPI AG 10.3390/cancers14041018
Moccia, Alden Alberto; Schär, Sämi; Hayoz, Stefanie; Pirosa, Maria Cristina; Taverna, Christian; Novak, Urban; Kimby, Eva; Ghielmini, Michele; Zucca, Emanuele (2021). Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). British journal of haematology, 192(6), pp. 1031-1034. Wiley-Blackwell 10.1111/bjh.17045
